久久一区二区三区四区_欧美高清dvd_日韩欧美在线看_国产精品欧美一区二区_av天天看_欧美精品免费观看二区

美國BellBrook Labs  
BellBrook Labs自2002年成立以來，一直向制藥公司提供高通量篩選工具，以加速有效療法的開發(fā)。在2005年，它開發(fā)了Transcreener分析平臺，打破了之前束縛藥物開發(fā)的瓶頸。這個分析平臺產(chǎn)生的數(shù)據(jù)能更好地預(yù)測病人對藥物的反應(yīng)，并改進(jìn)藥物靶點測試的企劃以及新藥治療的開展。在2007年，BellBrook Labs收購了Salus技術(shù)，來開發(fā)一種更新穎的技術(shù)平臺，使篩選實驗室能擴(kuò)大他們的細(xì)胞分析能力。通過提供創(chuàng)新的生物化學(xué)和細(xì)胞生物學(xué)技術(shù)，BellBrook能夠積極應(yīng)對藥物開發(fā)中面臨的種種挑戰(zhàn)。

BellBrook Labs is dedicated to providing the pharmaceutical industry with enabling screening tools to accelerate the discovery of more effective therapies. As a small, R&D-driven company, we identify areas where there is a strong need but a significant technical hurdle, and then we develop a solution. The company is focused on taking creative approaches to new product development and to continually improving the level of service provided to our customers. When you communicate with someone from BellBrook it will be immediately apparent that we share your passion for discovering more effective disease therapies and your respect for the complexity of biology. We have included names of BBL employees and direct phone numbers on this website. Please feel free to contact any of us with questions or suggestions regarding our products and technologies or how we might better serve your needs.

Transcreener? Biochemical Assay Technology: Our proprietary Transcreener? HTS Platform was developed to move more new targets into HTS more rapidly, and to streamline selectivity profiling within a target family. It relies on homogenous fluorescent immunodetection of nucleotides, including ADP, UDP, GDP, AMP and GMP, that are formed by thousands of cellular enzymes. Among these are group transferase families, such as kinases and glycosyltransferases, that catalyze the covalent regulatory reactions that are central to cell signaling. Each Transcreener Assay provides a generic detection method for multiple enzyme families. This means that you can focus on evaluating new therapeutic strategies and optimizing lead molecules rather than on time-consuming assay development for individual targets. Since introduction of the first Transcreener assays in 2005, the platform has been rapidly validated and adopted by pharmaceutical and biotechnology screening labs around the world.

iuvo? MicroConduit Array Technology: BellBrook is developing microscale cell culture devices with unique advantages for miniaturization and automation of cellular assays. These MicroConduit Arrays rely on liquid displacement from microchannels rather than the cumbersome aspiration and replacement used with open wells, yet they are compatible with existing liquid dispensing equipment. Applications will include invasion and migration assays and reconstruction of cells in complex three dimensional formats that recapitulate paracrine signaling in the context of native tissue.